BUZZ-Telehealth firms fall after Lilly launches single-dose vials of weight-loss drug

Reuters08-27

(Updates)

** Shares of telehealth firms Hims & Hers Health fall 5.7% to $15.14, LifeMD fall ~5% to $5.18, Teladoc Health down 1.2% at $7.23 in early trading

** Eli Lilly has begun selling single-dose vials of its weight-loss drug Zepbound in the U.S. through its LillyDirect website

** Zepbound's 2.5 milligram and 5 mg vials will be available at respective list prices of $399 and $549 for a month's supply - LLY

** HIMS offers compounded GLP-1 weight-loss injections at $199 per month

** "With Lilly now offering Zepbound at a near 50% discount to its autoinjector formulation through LillyDirect, (Zepbound) compounders are likely to be challenged more forcefully," said BMO Capital Markets analyst Evan Seigerman

** Lilly had sent

cease-and-desist letters

to U.S. healthcare providers earlier this month to stop promotion of compounded versions of its weight-loss and diabetes drugs

** Including session's moves, HIMS stock up ~72%, TDOC down ~66%, LFMD down ~38% YTD

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment